Systematic Reviews
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1578-1595
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1578
Table 1 Characteristics of included studies
Ref.
Cancer type
N
HSP
Age (yr)
Male (%)
Upper third cancer location (%)
Stage III/IV (%)
Follow-up (months)
Akutsu et al[21], 2011ESCC78HSP906289195124
Berezowska et al[22], 2013EA and G347HSP9069640NINI
Berg et al[23], 2011EA87HSP2063910NINI
Doak et al[24], 2004EA4HSP2063830NINI
Faried et al[25], 2004ESCC123HSP60, 9061861438NI
Huang et al[26], 2014ESCC81HSP905838030NI
Iqbal et al[27], 2016ESCC46HSP20, 70, 905865016NI
Kawanishi et al[28], 1999ESCC102HSP20, 706282NI3625
Liao et al[29], 2015ESCC134HSF16181NI46NI
Luz et al[30], 2017ESCC28HSP20, 706082NINI60
Lv et al[31], 2022ESCC and EA87HSP60NININI52NI
Miyazaki et al[32], 2005ESCC61HSP20, 706587214923
Nakajima et al[33], 2002ESCC62HSP20, 7061851342NI
Nakajima et al[34], 2009EC125HSP7062861438NI
Noguchi et al[35], 2002ESCC71HSP7064891145.
Ou et al[36], 2014ESCC328HSP905982NINI51
Söderström et al[37], 2019EA151HSP20, 706580083NI
Tsukao et al[38], 2017ESCC212HSF1, HSP20, 70, 9065871454NI
Wang et al[39], 2007G60HSP70, HSP9046530NINI
Wang et al[40], 2010ESCC120HSP70, 905777NININI
Wen et al[41], 2013ESCC234CHIP588310NI18
Xue et al[42], 2014ESCC112HSP206054NININI
Yu et al[43], 2015ESCC72HSP406582NI66NI
Zhang et al[44], 2013ESCC120HSP705375293660
Zhang et al[45], 2017ESCC162HSP206367NININI
Zhang et al[46], 2020ESCC345HSP20NI69NININI
Zhao et al[47], 2015ESCC113HSP7058822074NI
Table 2 Subgroup analysis, the impact of heat shock protein on 3-year overall survival, grade of cellular differentiation, and tumor-node-metastasis stage in esophageal squamous cell carcinoma
HSP

Overall survivall
Grade of cellular differentiation
T
N
M
CHIPRD (95%CI)0.03 (-0.09 to 0.15)--0.00 (0.00-0.00)-
Studies1--1-
HSF1RD (95%CI)-0.22 (-0.32 to -0.12)10.04 (-0.09 to 0.17)-0.22 (-0.51 to 0.06)-0.16 (-0.29 to -0.04)10.01 (-0.06 to 0.08)
Studies22121
HSP20RD (95%CI)0.16 (-0.12 to 0.45)0.03 (-0.05 to 0.11)0.01 (-0.13 to 0.16)-0.04 (-0.22 to 0.14)0.00 (0.15 to -0.15)
Studies67674
HSP40RD (95%CI)0.22 (0.09-0.35)10.03 (-0.10 to 0.16)-0.04 (-0.14 to 0.06)0.18 (0.03-0.33)10.03 (-0.05 to 0.11)
Studies11111
HSP60RD (95%CI)0.33 (0.17-0.50)1-0.03 (-0.20 to 0.13)0.09 (-0.09 to 0.26)-0.04 (-0.21 to 0.14)0.07 (-0.06 to 0.20)
Studies11111
HSP70RD (95%CI)0.07 (-0.18 to 0.31)-0.08 (-0.17 to 0.00)-0.07 (-0.25 to 0.11)-0.17 (-0.45 to 0.12)-0.10 (-0.33 to 0.12)
Studies88685
HSP90RD (95%CI)0.03 (-0.23 to 0.29)-0.02 (-0.06 to 0.03)-0.10 (-0.20 to 0.01)-0.24 (-0.74 to 0.26)0.18 (-0.18 to 0.54)
Studies32433
Table 3 Risk of bias assessment scores based on the Newcastle-Ottawa Scale of studies
Ref.Selection of cohorts
Comparability of cohorts
Outcome
Representativeness of the exposed cohort
Selection of the non-exposed cohort
Ascertainment of exposure
Demonstration that outcome of interest was not present at start of study
Comparability of cohorts on the basis of the design or analysis
Assessment of outcome
Was follow up long enough for outcomes to occur
Adequacy of follow up of cohorts
Akutsu et al[21], 2011☆☆
Berezowska et al[22], 2013☆☆
Berg et al[23], 2011☆☆
Doak et al[24], 2004☆☆
Faried et al[25], 2004
Huang et al[26], 2014☆☆
Iqbal et al[27], 2016☆☆
Kawanishi et al[28], 1999☆☆
Liao et al[29], 2015☆☆
Luz et al[30], 2017☆☆
Lv et al[31], 2022☆☆
Miyazaki et al[32], 2005☆☆
Nakajima et al[33], 2002☆☆
Nakajima et al[34], 2009☆☆
Noguchi et al[35], 2002☆☆
Ou et al[36], 2014☆☆
Söderström et al[37], 2019☆☆
Tsukao et al[38], 2017☆☆
Wang et al[39], 2007☆☆
Wang et al[40], 2010☆☆
Wen et al[41], 2013☆☆
Xue et al[42], 2014☆☆
Yu et al[43], 2015☆☆
Zhang et al[44], 2013☆☆
Zhang et al[45], 2017☆☆
Zhang et al[46], 2020☆☆
Zhao et al[47], 2015☆☆